محمد حسام|МŐĤĂММĔĎ ĤŐŚŚĂМ

I talked to a pharma executive last week. Big company, UK based, he runs things from what I think is the Middle East control room in Jeddah. Senior guy, more than a decade in the industry. I asked him the obvious question, how is he using AI day to day. He does not, not really. He uses Copilot to proofread emails and juggle the occasional idea, because Copilot is the only thing his work laptop will let him touch. He told me he thought about running a second laptop off the company firewall so he could actually explore what is out there, but keeping two work laptops was too much of a hassle. So he stayed on one laptop, inside the firewall, and stayed a chatbot user. That is not a story about one lazy executive. That is a story about an entire class of sectors, heavy IP, heavy security, heavy regulation, where the friction of adopting anything beyond a sanctioned chatbot is high enough that the frontier simply does not reach them yet. Pharma, medicine, anywhere production touches actu...

If you scroll tech Twitter, the discourse is dominated by "tokenmaxing" — people flexing multi-million token usage, chaining complex autonomous agent loops, and obsessing over API token throughput. But far away from that hype, how does AI function in a real enterprise setting where revenue, accuracy, and client relationships are on the line? I recently had a deep conversation with a medical professional who offers a grounded perspective missing from mainstream tech discussions. He is a co-founder of a medical communications agency based in Jeddah, working face-to-face with major pharmaceutical companies and healthcare professionals. His agency bridges the gap between medical science and advertising — building research-backed, highly regulated campaigns. Having worked in the industry for over a decade — spanning 9-to-5 corporate roles, freelancing, and now running an agency — his experience provides a clear benchmark for where AI provides genuine leverage, where it expos...